Luye Pharma Group Ltd. (2186.HK)

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by trauma or surgery, and for treatment of venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes mellitus; Seroquel, Seroquel XR, Erzofri; and Rivastigmine Multi-Day Transdermal, Rotigotine transdermal, Fentanyl, and Buprenorphine patches. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Boyoubei, a denosumab injection for the treatment of postmenopausal women with osteoporosis; and Boyouping, a dulaglutide injection for glycemic control in adults. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; develops, manufactures, and commercialises of biologics; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.